The 6-N-heterocyclic naltrexamine derivative, NAP, continues to be proven a peripherally selective mu opioid receptor modulator. optimum response at 45.9 1.7% of U50,488H. BNAP didn’t change morphine-induced antinociception when implemented subcutaneously but do antagonize when implemented intracerebroventricularly. BNAP antagonized morphine-induced contractions from the round muscles in mice digestive tract. BNAP inhibition of field-stimulated contractions in… Continue reading The 6-N-heterocyclic naltrexamine derivative, NAP, continues to be proven a peripherally